Grassi Investment Management Has Upped Its Disney Walt Co (DIS) Position; Immunogen (IMGN) Shorts Raised By 10.57%

July 5, 2017 - By Kurt Siggers

Immunogen Incorporated (NASDAQ:IMGN) had an increase of 10.57% in short interest. IMGN’s SI was 14.10M shares in July as released by FINRA. Its up 10.57% from 12.76 million shares previously. With 1.86 million avg volume, 8 days are for Immunogen Incorporated (NASDAQ:IMGN)’s short sellers to cover IMGN’s short positions. The stock decreased 4.22% or $0.3 on July 3, reaching $6.81. About shares traded. ImmunoGen, Inc. (NASDAQ:IMGN) has declined 3.49% since July 5, 2016 and is downtrending. It has underperformed by 20.19% the S&P500.

Grassi Investment Management increased Disney Walt Co (DIS) stake by 1132.23% reported in 2016Q4 SEC filing. Grassi Investment Management acquired 49,105 shares as Disney Walt Co (DIS)’s stock declined 2.31%. The Grassi Investment Management holds 53,442 shares with $5.57M value, up from 4,337 last quarter. Disney Walt Co now has $170.08 billion valuation. The stock increased 1.14% or $1.21 during the last trading session, reaching $107.46. About 60 shares traded. Walt Disney Co (NYSE:DIS) has risen 9.26% since July 5, 2016 and is uptrending. It has underperformed by 7.44% the S&P500.

Since January 6, 2017, it had 0 insider purchases, and 6 insider sales for $95.94 million activity. The insider BRAVERMAN ALAN N sold $10.19M. $184,810 worth of Walt Disney Co (NYSE:DIS) was sold by WOODFORD BRENT. Another trade for 1,893 shares valued at $208,295 was made by LEWIS AYLWIN B on Tuesday, February 21. $1.32M worth of Walt Disney Co (NYSE:DIS) was sold by ARNOLD SUSAN E on Thursday, May 11. $83.82M worth of Walt Disney Co (NYSE:DIS) shares were sold by IGER ROBERT A.

Investors sentiment increased to 1.13 in Q4 2016. Its up 0.10, from 1.03 in 2016Q3. It improved, as 67 investors sold DIS shares while 602 reduced holdings. 166 funds opened positions while 593 raised stakes. 928.49 million shares or 5.48% more from 880.26 million shares in 2016Q3 were reported. Triangle Wealth Mngmt stated it has 27,914 shares or 1.94% of all its holdings. The Texas-based Salient Lta has invested 1.33% in Walt Disney Co (NYSE:DIS). 25,443 were accumulated by Pvg Asset. Northwest Counselors Limited Liability Corp, Oregon-based fund reported 20,001 shares. Swiss Bancorporation has 4.25M shares. Hodges has invested 0.07% in Walt Disney Co (NYSE:DIS). Maple Management owns 5,629 shares. Sandler Capital stated it has 60,370 shares or 0.56% of all its holdings. 4,245 were reported by Mark Sheptoff Finance Planning Ltd Company. Kames Public Ltd Co invested in 7,088 shares. Pinnacle Financial Prtn owns 40,514 shares. American Rech And Mngmt Co holds 0.02% or 602 shares in its portfolio. Pettyjohn Wood & White holds 1.89% in Walt Disney Co (NYSE:DIS) or 46,805 shares. America First Inv Limited Liability Company reported 0% of its portfolio in Walt Disney Co (NYSE:DIS). Farmers Company owns 49,445 shares for 1.78% of their portfolio.

Among 33 analysts covering The Walt Disney Company (NYSE:DIS), 18 have Buy rating, 2 Sell and 13 Hold. Therefore 55% are positive. The Walt Disney Company has $138 highest and $10.55 lowest target. $115.49’s average target is 7.47% above currents $107.46 stock price. The Walt Disney Company had 90 analyst reports since July 24, 2015 according to SRatingsIntel. Argus Research maintained Walt Disney Co (NYSE:DIS) rating on Monday, November 9. Argus Research has “Buy” rating and $129 target. Goldman Sachs upgraded it to “Buy” rating and $134 target in Tuesday, January 17 report. The rating was downgraded by Loop Capital to “Hold” on Monday, April 24. The rating was upgraded by Guggenheim to “Buy” on Tuesday, March 14. The rating was downgraded by Guggenheim on Monday, November 16 to “Neutral”. As per Friday, November 11, the company rating was downgraded by Pivotal Research. The rating was maintained by Barclays Capital with “Hold” on Sunday, August 16. The stock has “Hold” rating by Deutsche Bank on Thursday, February 18. The company was maintained on Monday, May 15 by Loop Capital. The firm earned “Buy” rating on Wednesday, November 16 by Deutsche Bank.

ImmunoGen, Inc. is a clinical-stage biotechnology firm that develops targeted cancer therapeutics using its antibody-drug conjugate technology. The company has market cap of $582.79 million. The Firm is engaged in the discovery of monoclonal antibody anticancer therapeutics. It currently has negative earnings. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.

Investors sentiment increased to 1.14 in Q4 2016. Its up 0.30, from 0.84 in 2016Q3. It improved, as 20 investors sold ImmunoGen, Inc. shares while 37 reduced holdings. 21 funds opened positions while 44 raised stakes. 64.19 million shares or 12.81% less from 73.62 million shares in 2016Q3 were reported. Northeast Consultants owns 0.03% invested in ImmunoGen, Inc. (NASDAQ:IMGN) for 34,315 shares. Carroll Financial Associates holds 0% or 209 shares. Swiss Bank & Trust stated it has 159,400 shares or 0% of all its holdings. Fisher Asset Mngmt Limited Liability Co has invested 0% in ImmunoGen, Inc. (NASDAQ:IMGN). Comerica Bank & Trust stated it has 0% in ImmunoGen, Inc. (NASDAQ:IMGN). Alliancebernstein Lp has invested 0% of its portfolio in ImmunoGen, Inc. (NASDAQ:IMGN). Fmr Ltd Company owns 802,029 shares. Legal And General Public Limited Liability Company invested in 0% or 28,065 shares. Rhumbline Advisers invested in 106,169 shares. Prudential Fin invested 0% in ImmunoGen, Inc. (NASDAQ:IMGN). 2.22M were accumulated by Millennium Mngmt Limited Liability Corporation. Fifth Third Fincl Bank stated it has 6,700 shares or 0% of all its holdings. Amalgamated Bancorporation accumulated 10,332 shares. Alexandria Capital Lc stated it has 57 shares. Bnp Paribas Arbitrage Sa invested 0% in ImmunoGen, Inc. (NASDAQ:IMGN).

Among 6 analysts covering Immunogen (NASDAQ:IMGN), 2 have Buy rating, 1 Sell and 3 Hold. Therefore 33% are positive. Immunogen has $24 highest and $500 lowest target. $10.60’s average target is 55.65% above currents $6.81 stock price. Immunogen had 9 analyst reports since August 3, 2015 according to SRatingsIntel. On Monday, July 27 the stock rating was maintained by RBC Capital Markets with “Outperform”. The stock of ImmunoGen, Inc. (NASDAQ:IMGN) has “Neutral” rating given on Monday, August 3 by Cantor Fitzgerald. RBC Capital Markets downgraded it to “Sector Perform” rating and $7 target in Friday, April 29 report. The rating was maintained by Leerink Swann with “Market Perform” on Monday, May 2. Morgan Stanley downgraded the stock to “Underweight” rating in Monday, September 21 report. Leerink Swann maintained it with “Market Perform” rating and $14 target in Wednesday, October 28 report. The firm earned “Hold” rating on Tuesday, May 30 by Cantor Fitzgerald. The firm earned “Buy” rating on Wednesday, November 25 by Jefferies. Oppenheimer maintained ImmunoGen, Inc. (NASDAQ:IMGN) rating on Wednesday, July 29. Oppenheimer has “Outperform” rating and $24 target.